Eli Lilly and Company (NYSE:LLY) is one of the best long term stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) announced on March 16 positive topline results from the Phase 3 ADorable-1 trial that was evaluating the safety and efficacy of EBGLYSS in pediatric patients with moderate-to-severe atopic dermatitis. Management stated that EBGLYSS met the primary and key secondary endpoints at Week 16, improving disease severity while delivering skin clearance and relief from persistent itch. Eli Lilly and Company (NYSE:LLY) has plans to submit the data to U.S. and global regulators for a potential label update.

In a separate development, Eli Lilly and Company (NYSE:LLY) was downgraded to Reduce from Hold by HSBC on March 17, with the firm bringing the price target on the stock down to $850 from $1,070. The firm told investors in a research note that it believes expectations for the total addressable market for obesity are elevated at over $150 billion, and the market is likely to be in the range of $80 billion -$120 billion by 2032, with price competition “ likely to be significant”.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.